Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects
- PMID: 8162610
- PMCID: PMC11038506
- DOI: 10.1007/BF01525505
Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects
Abstract
ONO-4007 is a novel synthetic analog of lipid A subunit and has been shown to exert antitumor activities on various experimental tumors with less toxicity than lipopolysaccharide. It remains unclear, however, what biological activities of this compound are relevant to its antitumor effects. We therefore investigated the activation of macrophages by ONO-4007 in vitro and in vivo and its implication in antitumor effects, using mouse MM46 mammary tumor as an experimental model. Intravenous injection of ONO-4007 produced significant therapeutic effects on this solid tumor. ONO-4007 could stimulate glycogen-elicited peritoneal macrophages in vitro, not only to produce tumor necrosis factor (TNF), but also to exert cytocidal activities against MM46 cells in vitro. Substantial TNF production was induced in tumor tissue by i. v. injection of ONO-4007, and its successive administration to tumor-bearing mice gave tumor-infiltrating macrophages a prominent in vitro tumoricidal activity and primed them for in vitro TNF secretion. These results suggest that activation of tumor-infiltrating macrophages to a direct tumoricidal state as well as to TNF secretion in tumor tissues may be at least some of the antitumor effects of this novel lipid A analog.
Similar articles
-
Induction of intratumoral tumor necrosis factor by a synthetic lipid A analog, ONO-4007, with less tolerance in repeated administration and its implication in potent antitumor effects with low toxicity.Cancer Immunol Immunother. 2002 Feb;50(12):653-62. doi: 10.1007/s00262-001-0241-7. Epub 2001 Dec 6. Cancer Immunol Immunother. 2002. PMID: 11862417 Free PMC article.
-
Synthetic lipid A produces antitumor effect in a hamster pancreatic carcinoma model through production of tumor necrosis factor from activated macrophages.Kobe J Med Sci. 1996 Aug;42(4):219-31. Kobe J Med Sci. 1996. PMID: 9023454
-
A new synthetic lipid A analog, ONO-4007, stimulates the production of tumor necrosis factor-alpha in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells.Anticancer Drugs. 1997 Jun;8(5):500-8. doi: 10.1097/00001813-199706000-00013. Anticancer Drugs. 1997. PMID: 9215614
-
Therapeutic effect of a new synthetic lipid A analog (ONO-4007) on a tumor implanted at different sites in rats.J Immunother. 1999 Sep;22(5):401-6. doi: 10.1097/00002371-199909000-00003. J Immunother. 1999. PMID: 10546155
-
Intratumoral tumor necrosis factor induction and tumor growth suppression by ONO-4007, a low-toxicity lipid A analog.Anticancer Res. 1998 Nov-Dec;18(6A):4283-9. Anticancer Res. 1998. PMID: 9891479
Cited by
-
A synthetic lipid A mimetic modulates human TLR4 activity.ChemMedChem. 2012 Feb 6;7(2):213-7. doi: 10.1002/cmdc.201100494. Epub 2011 Dec 2. ChemMedChem. 2012. PMID: 22140087 Free PMC article. No abstract available.
-
Role of inflammatory mediators in lipid A analogue (ONO-4007)-induced vascular permeability change in mouse skin.Br J Pharmacol. 2000 Jul;130(6):1235-40. doi: 10.1038/sj.bjp.0703425. Br J Pharmacol. 2000. PMID: 10903960 Free PMC article.
-
Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.Br J Cancer. 1999 May;80(5-6):716-23. doi: 10.1038/sj.bjc.6690415. Br J Cancer. 1999. PMID: 10360649 Free PMC article.
-
A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors.Jpn J Cancer Res. 1999 Sep;90(9):1016-25. doi: 10.1111/j.1349-7006.1999.tb00850.x. Jpn J Cancer Res. 1999. PMID: 10551333 Free PMC article.
-
Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats.Clin Exp Metastasis. 1999 Jun;17(4):299-306. doi: 10.1023/a:1006663017149. Clin Exp Metastasis. 1999. PMID: 10545016
References
-
- Abe S, Yoshioka O, Masuko Y, Tsubouchi J, Kohno M, Nakajima H, Yamazaki M, Mizuno D. Combination antitumor therapy with lentinan and bacterial lipopolysaccharide against murine tumors. Gann. 1982;73:91. - PubMed
-
- Abe S, Tubouchi J, Takahashi K, Yamazaki M, Mizuno D. Combination therapy of murine tumors with lentinan plus lipopolysaccharide plus cyclophosphamide. Gann. 1982;73:961. - PubMed
-
- Branellec D, Chouaib S. TNF: antitumoral agent at the borderlines of immunity and inflammation. Pathol Biol (Paris) 1991;39:230. - PubMed
-
- Cameron DJ, Strimberg BV. The ability of macrophages from head and neck cancer patients to kill tumor cells. Cancer. 1984;54:2403. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources